223 related articles for article (PubMed ID: 15810646)
21. Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon.
Tursi A; Brandimarte G; Giorgetti GM; Elisei W
Hepatogastroenterology; 2008; 55(84):916-20. PubMed ID: 18705297
[TBL] [Abstract][Full Text] [Related]
22. Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon.
Tursi A; Brandimarte G; Giorgetti GM; Elisei W
Dig Dis Sci; 2007 Mar; 52(3):671-4. PubMed ID: 17253134
[TBL] [Abstract][Full Text] [Related]
23. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study.
Tursi A; Brandimarte G; Giorgetti GM; Elisei W
J Clin Gastroenterol; 2006 Apr; 40(4):312-6. PubMed ID: 16633103
[TBL] [Abstract][Full Text] [Related]
24. Quality of life in uncomplicated symptomatic diverticular disease: is it another good reason for treatment?
Comparato G; Fanigliulo L; Aragona G; Cavestro GM; Cavallaro LG; Leandro G; Pilotto A; Nervi G; Soliani P; Sianesi M; Franzé A; Di Mario F
Dig Dis; 2007; 25(3):252-9. PubMed ID: 17827951
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of long term cyclic administration of the poorly absorbed antibiotic Rifaximin in symptomatic, uncomplicated colonic diverticular disease.
Colecchia A; Vestito A; Pasqui F; Mazzella G; Roda E; Pistoia F; Brandimarte G; Festi D
World J Gastroenterol; 2007 Jan; 13(2):264-9. PubMed ID: 17226906
[TBL] [Abstract][Full Text] [Related]
26. Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon.
Tursi A; Papa A; Danese S
Aliment Pharmacol Ther; 2015 Sep; 42(6):664-84. PubMed ID: 26202723
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular disease.
Bianchi M; Festa V; Moretti A; Ciaco A; Mangone M; Tornatore V; Dezi A; Luchetti R; De Pascalis B; Papi C; Koch M
Aliment Pharmacol Ther; 2011 Apr; 33(8):902-10. PubMed ID: 21366632
[TBL] [Abstract][Full Text] [Related]
28. Mesalazine for the Treatment of Symptomatic Uncomplicated Diverticular Disease of the Colon and for Primary Prevention of Diverticulitis: A Systematic Review of Randomized Clinical Trials.
Picchio M; Elisei W; Brandimarte G; Di Mario F; Malfertheiner P; Scarpignato C; Tursi A
J Clin Gastroenterol; 2016 Oct; 50 Suppl 1():S64-9. PubMed ID: 27622370
[TBL] [Abstract][Full Text] [Related]
29. Treatment of diverticular disease of the colon and prevention of acute diverticulitis: a systematic review.
Maconi G; Barbara G; Bosetti C; Cuomo R; Annibale B
Dis Colon Rectum; 2011 Oct; 54(10):1326-38. PubMed ID: 21904150
[TBL] [Abstract][Full Text] [Related]
30. Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon--a placebo-controlled study.
Kruis W; Meier E; Schumacher M; Mickisch O; Greinwald R; Mueller R;
Aliment Pharmacol Ther; 2013 Apr; 37(7):680-90. PubMed ID: 23414061
[TBL] [Abstract][Full Text] [Related]
31. Management of diverticular disease: is there room for rifaximin?
Papi C; Koch M; Capurso L
Chemotherapy; 2005; 51 Suppl 1():110-4. PubMed ID: 15855755
[TBL] [Abstract][Full Text] [Related]
32. Budesonide MMX Is Effective in Patients Having Persistent Symptoms and Raised Fecal Calprotectin Following Treatments for Diverticular Disease.
Tursi A; Cassieri C; Colucci R; Elisei W; Picchio M; Brandimarte G
J Gastrointestin Liver Dis; 2019 Dec; 28(suppl. 4):45-48. PubMed ID: 31930223
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of different therapeutic strategies in preventing diverticulitis recurrence.
Tursi A; Elisei W; Giorgetti GM; Inchingolo CD; Nenna R; Picchio M; Maiorano M; Penna A; Lecca PG; Brandimarte G
Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):342-8. PubMed ID: 23426537
[TBL] [Abstract][Full Text] [Related]
34. Acute recurrent diverticulitis is prevented by oral administration of a polybacterial lysate suspension.
Dughera L; Serra AM; Battaglia E; Tibaudi D; Navino M; Emanuelli G
Minerva Gastroenterol Dietol; 2004 Jun; 50(2):149-53. PubMed ID: 15722985
[TBL] [Abstract][Full Text] [Related]
35. The influence of rifaximin on diverticulitis rate and quality of life in patients with diverticulosis.
Banasiewicz T; Francuzik W; Bobkiewicz A; Krokowicz Ł; Borejsza-Wysocki M; Paszkowski J; Studniarek A; Krokowicz P; Grochowalski M; Szczepkowski M; Lorenc Z
Pol Przegl Chir; 2017 Feb; 89(1):22-31. PubMed ID: 28522790
[TBL] [Abstract][Full Text] [Related]
36. Review article: the current and evolving treatment of colonic diverticular disease.
Tursi A; Papagrigoriadis S
Aliment Pharmacol Ther; 2009 Sep; 30(6):532-46. PubMed ID: 19549266
[TBL] [Abstract][Full Text] [Related]
37. Epithelial cell proliferation of the colonic mucosa in diverticular disease: a case-control study.
Morini S; Hassan C; Zullo A; De Francesco V; Burattini O; Margiotta M; Panella C; Ierardi E
Aliment Pharmacol Ther; 2005 Jun; 21(11):1385-90. PubMed ID: 15932369
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the effect of rifaximin in colon diverticular disease by means of lactulose hydrogen breath test.
Ventrucci M; Ferrieri A; Bergami R; Roda E
Curr Med Res Opin; 1994; 13(4):202-6. PubMed ID: 7882699
[TBL] [Abstract][Full Text] [Related]
39. Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon.
Di Mario F; Miraglia C; Cambiè G; Violi A; Nouvenne A; Franceschi M; Brandimarte G; Elisei W; Picchio M; Tursi A
J Investig Med; 2019 Apr; 67(4):767-770. PubMed ID: 30593541
[TBL] [Abstract][Full Text] [Related]
40. Uncomplicated diverticular disease: innate and adaptive immunity in human gut mucosa before and after rifaximin.
Cianci R; Frosali S; Pagliari D; Cesaro P; Petruzziello L; Casciano F; Landolfi R; Costamagna G; Pandolfi F
J Immunol Res; 2014; 2014():696812. PubMed ID: 25133198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
